Figure 2.

The Cat-315 epitope level on RPTPβ is reduced in GnT-IX-deficient mice. A, Brain lysates from wild-type (WT) and GnT-IX-deficient (KO) mice at 2 weeks of age (2 Wks) or 8–12 months of age (Adult) were analyzed by Western blotting with anti-HNK-1 and anti-GAPDH antibodies. B, Brain lysates from WT mice at 2 weeks of age were incubated in the presence or absence of PNGase and/or chondroitinase ABC (CHase ABC), or treated with TFMS, and then analyzed by Western blotting with the Cat-315 antibody. C, RPTPβ immunoprecipitated from brain microsomal fractions of WT and GnT-IX-deficient mice were analyzed by Western blotting with Cat-315 and anti-RPTPβ antibodies. D, Graph representing the relative signal intensities of Cat-315/RPTPβ in the immunoprecipitates with the anti-RPTPβ antibody. The data shown are means ± SEM (n = 5). *p < 0.005. E, Immunoprecipitated aggrecan from brain lysates was analyzed as described for RPTPβ (C). F, Graph representing the relative signal intensities of Cat-315/aggrecan in the immunoprecipitates with the anti-aggrecan antibody. The data shown are means ± SEM (n = 5).